GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SomnoMed Ltd (ASX:SOM) » Definitions » EV-to-EBIT

SomnoMed (ASX:SOM) EV-to-EBIT : -9.98 (As of May. 16, 2024)


View and export this data going back to 2004. Start your Free Trial

What is SomnoMed EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SomnoMed's Enterprise Value is A$64.05 Mil. SomnoMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.42 Mil. Therefore, SomnoMed's EV-to-EBIT for today is -9.98.

The historical rank and industry rank for SomnoMed's EV-to-EBIT or its related term are showing as below:

ASX:SOM' s EV-to-EBIT Range Over the Past 10 Years
Min: -314.8   Med: 108.67   Max: 551.62
Current: -9.98

During the past 13 years, the highest EV-to-EBIT of SomnoMed was 551.62. The lowest was -314.80. And the median was 108.67.

ASX:SOM's EV-to-EBIT is ranked worse than
100% of 460 companies
in the Medical Devices & Instruments industry
Industry Median: 20.415 vs ASX:SOM: -9.98

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. SomnoMed's Enterprise Value for the quarter that ended in Dec. 2023 was A$60.00 Mil. SomnoMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.42 Mil. SomnoMed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -10.70%.


SomnoMed EV-to-EBIT Historical Data

The historical data trend for SomnoMed's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomnoMed EV-to-EBIT Chart

SomnoMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.62 86.91 -267.20 -26.79 -18.26

SomnoMed Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -26.79 - -18.26 -

Competitive Comparison of SomnoMed's EV-to-EBIT

For the Medical Devices subindustry, SomnoMed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SomnoMed's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SomnoMed's EV-to-EBIT falls into.



SomnoMed EV-to-EBIT Calculation

SomnoMed's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=64.049/-6.419
=-9.98

SomnoMed's current Enterprise Value is A$64.05 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SomnoMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SomnoMed  (ASX:SOM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

SomnoMed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-6.419/59.9956716
=-10.70 %

SomnoMed's Enterprise Value for the quarter that ended in Dec. 2023 was A$60.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SomnoMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SomnoMed EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of SomnoMed's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


SomnoMed (ASX:SOM) Business Description

Traded in Other Exchanges
Address
20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd produces and sells oral treatment of sleep-related disorder devices. It manufactures and designs premium oral appliances for the treatment of sleep-disordered breathing relieving conditions. Its products include SomnoDent, Som Tabs, Som Morning Repositioner and others. Its geographical segments include North America, Europe, and Asia-Pacific. Business operations consist of the production and sale of products treating sleep-disordered breathing, which is the only reportable segment. Substantial revenue is realized from the European region.

SomnoMed (ASX:SOM) Headlines

No Headlines